Arvinas and Pfizer announce initial Phase 1b Data from the TACTIVE-U sub-study of Vepdegestrant in… EP News Bureau Dec 11, 2024 Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5 per cent;…
Eli Lilly introduces Ramiven (abemaciclib) in India EP News Bureau Nov 25, 2022 Abemaciclib is a CDK4/6 inhibitor which has now been approved for HR+ HER2 - node positive high-risk Early Breast Cancer (EBC)
